Page 269 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

List of Publications timing and criteria of interim PET in DLBCL: a comparative study of 1692
patients. Blood Adv. 2021 May 11;5(9):2375-2384.
Zwezerijnen GJC, Eertink JJ, Burggraaff CN, Wiegers SE, Shaban EAIN, Pieplenbosch S, Oprea-Lager DE, Lugtenburg PJ, Hoekstra OS, de Vet HCW, Zijlstra JM, Boellaard R. Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma. J Nucl Med. 2021 Nov;62(11):1531-1536.
Eertink JJ, Arens AIJ, Huijbregts JE, Celik F, de Keizer B, Stroobants S, de Jong D, Wiegers SE, Zwezerijnen GJC, Burggraaff CN, Boellaard R, de Vet HCW, Hoekstra OS, Lugtenburg PJ, Chamuleau MED, Zijlstra JM; HOVON imaging workgroup. Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements. Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):943-952.
Greuter M, Eertink JJ, Jongeneel G, Dührsen U, Hüttmann A, Schmitz C, Lugtenburg PJ, Barrington SF, Mikhaeel NG, Ceriani L, Zucca E, Carr R, Györke T, Burggraaff CN, de Vet H, Hoekstra OS, Zijlstra JM, Coupé V; PETRA consortium. Cost-Effectiveness of Shortening Treatment Duration Based on Interim PET Outcome in Patients With Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2022 Jun;22(6):382-392.
Burggraaff CN, Eertink JJ, Lugtenburg PJ, Hoekstra OS, Arens AIJ, de Keizer B, Heymans MW, van der Holt B, Wiegers SE, Pieplenbosch S, Boellaard R, de Vet HCW, Zijlstra JM; HOVON Imaging Working Group and the HOVON Lymphoma Working Group. 18F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study. J Nucl Med. 2022 Jul;63(7):1001-1007.
267
A